| CAS NO: | 1648843-04-2 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 2mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| Molecular Weight (MW) | 467.20 |
|---|---|
| Formula | C19H14BF4N3O4S |
| CAS No. | 1648843-04-2 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 10mM |
| Water: <1 mg/mL | |
| Ethanol: <1 mg/mL | |
| Chemical Name | (2-(((5-((4-fluorophenyl)carbamoyl)pyrimidin-2-yl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid |
| Synonyms | SX-682; SX 682; SX682 |
| SMILES Code | O=C(C1=CN=C(SCC2=CC(OC(F)(F)F)=CC=C2B(O)O)N=C1)NC3=CC=C(F)C=C3 |
| In Vitro | In vitro activity: SX-682 is a novel, potent and selective CXCR2 chemokine receptor antagonist with potential anticancer activities. The CXC chemokine receptor CXCR2 is upregulated in a variety of different tumor cell types and involved in tumor cell proliferation and progression. Inhibition of CXCR2 led to reduced metastasis and decreased tumorigenesis. As a CXCR2 antagonist, SX-682 has the potential to treat cancer such as castration-resistant prostate cancer and melanoma. SX-682 in combination with pembrolizumab for the treatment of metastatic melanoma is starting phase I clinical trial by Syntrix Biosystems, Inc. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | SX-682 was orally administered twice a day at 50 mg/kg actual dose on a Monday through Friday schedule. Similar drug dosing methods were described previously |
| Animal model | |
| Formulation & Dosage | 50 mg/kg; p.o. |
| References | Nature. 2017 Mar 30;543(7647):728-732. |
m.cnreagent.com